LOS ANGELES- Optimi Health Corp. a Canadian company recognized for its work in controlled psychedelic substances such as natural psilocybin and MDMA, has announced a significant supply agreement with Sunshine Earth Labs Ltd., a British Columbia-based biosciences company also licensed by Health Canada. This strategic alliance highlights a commitment to supplying globally the Good Manufacturing Practice (GMP) quality-controlled substances for medicinal and research applications.
Bill Ciprick, CEO of Optimi, sees this partnership as a formidable union in the tightly regulated psychedelics market. “Our alignment with Sunshine Labs opens opportunities to harness our collective contacts and connections, addressing the global demand for GMP drug substances for research purposes on a meaningful scale,” Ciprick stated. The collaboration between these two reputable British Columbian companies underscores the region’s prominence as a leader in psychedelic research and development.
Donovan Edwards, CEO of Sunshine Labs, emphasized the partnership’s goal of providing a safe and secure global supply of controlled substances. “Together, we are poised to create a robust pipeline for delivering high-quality psychedelics to the current accessible international market, setting new standards for innovation and reliability,” Edwards remarked. Sunshine Labs is dedicated to sourcing and delivering the highest quality psychedelic medication for addiction treatment on a global scale, a mission that Optimi strongly supports.
The agreement entails Optimi’s commitment to manufacturing and supplying Sunshine Labs with Full Spectrum Active Pharmaceutical Ingredient (API) and encapsulated psilocybin product, as well as encapsulated MDMA. These products will be produced in Optimi’s 10,000 sq ft, state-of-the-art facility in Princeton, British Columbia. The quantities to be purchased under this agreement will be determined based on the evolving market needs.
Both companies adhere to the stringent standards of GMP drug production as required by Health Canada under the Controlled Drugs and Substances Act (CDSA) and Part C, Division 2 of the Food and Drug Regulations. This partnership represents a significant step in addressing the global demand for controlled psychedelic substances for medicinal and research purposes, contributing to the advancement of treatment options and scientific understanding in this field.
